We are live on ! Find out more
2L

22NW LP Portfolio holdings

AUM $146M
1-Year Est. Return 29.83%
This Fund
S&P 500
This Quarter Est. Return
+43.2%
1 Year Est. Return
+29.83%
3 Year Est. Return
+131.37%
5 Year Est. Return
+199.25%
10 Year Est. Return
–
AUM
$212M
AUM Growth
+$53.5M
Cap. Flow
+$6.11M
Cap. Flow %
2.88%
Top 10 Hldgs %
81.63%
Holding
23
New
2
Increased
4
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$6.12M
2
RZLT icon
Rezolute
RZLT
+$5.46M
3
AEBI
Aebi Schmidt Holding AG
AEBI
+$4.38M
4
MEC icon
Mayville Engineering Co
MEC
+$3.68M
5
SRI icon
Stoneridge
SRI
+$1.28M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$4.36M
2
DHX icon
DHI Group
DHX
+$3.49M
3
ARVN icon
Arvinas
ARVN
+$3.04M
4
CMPS
Compass Pathways
CMPS
+$2.47M
5
LFCR icon
Lifecore Biomedical
LFCR
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 54.67%
2 Industrials 22.64%
3 Consumer Discretionary 13.66%
4 Technology 2.67%
5 Financials 2.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANEB
1
DELISTED
Anebulo Pharmaceuticals
ANEB
$38.7M 18.22%
15,467,300
– –
FSTR icon
2
Foster
FSTR
$443M
$35.4M 16.67%
1,313,121
– –
LFCR icon
3
Lifecore Biomedical
LFCR
$162M
$20.1M 9.49%
1,254
-262,926
-100% -$1.99M
NKTR icon
4
Nektar Therapeutics
NKTR
$2.39B
$18.8M 8.88%
331,115
+185,000
+127% +$6.12M
SRI icon
5
Stoneridge
SRI
$209M
$16M 7.56%
2,105,600
+162,092
+8% +$1.28M
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.35B
$13.6M 6.4%
358,325
-201,717
-36% -$4.36M
RGNX icon
7
Regenxbio
RGNX
$623M
$8.91M 4.2%
923,679
– –
CULP icon
8
Culp Inc
CULP
$45M
$8.29M 3.91%
1,859,061
– –
RZLT icon
9
Rezolute
RZLT
$480M
$7.71M 3.63%
+820,653
New +$5.46M
DHX icon
10
DHI Group
DHX
$166M
$5.66M 2.67%
2,036,988
-1,262,949
-38% -$3.49M
PFX icon
11
PhenixFIN
PFX
$5.6M 2.64%
117,885
– –
MEC icon
12
Mayville Engineering Co
MEC
$772M
$5.5M 2.59%
399,890
+244,440
+157% +$3.68M
MGTX icon
13
MeiraGTx Holdings
MGTX
$1.09B
$4.83M 2.27%
586,519
– –
UFI icon
14
UNIFI
UFI
$117M
$4.65M 2.19%
977,639
-3,896
-0.4% -$18K
CMT icon
15
Core Molding Technologies
CMT
$210M
$4.58M 2.16%
222,738
+31,516
+16% +$585K
AEBI
16
Aebi Schmidt Holding AG
AEBI
$1.01B
$4.34M 2.04%
+347,840
New +$4.38M
FARM
17
DELISTED
Farmer Brothers
FARM
$3.34M 1.58%
1,955,526
– –
TISI icon
18
Team
TISI
$77.7M
$2.82M 1.33%
170,187
-903
-0.5% -$16.2K
ELDN icon
19
Eledon Pharmaceuticals
ELDN
$276M
$1.65M 0.78%
636,364
– –
SSKN
20
DELISTED
Strata Skin Sciences
SSKN
$1.11M 0.52%
536,995
– –
PMD
21
DELISTED
Psychemedics Corporation
PMD
$582K 0.27%
276,034
– –
ARVN icon
22
Arvinas
ARVN
$518M
– –
-413,533
Closed -$3.04M
CMPS
23
Compass Pathways
CMPS
$1.52B
– –
-882,844
Closed -$2.47M

Similar funds

TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
AFM
Aspetuck Financial Management Westport, Connecticut $146M AUM 33.29% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
AWM
Apex Wealth Management Bedford, New Hampshire $146M AUM 15.52% 1-Year Est. Return
AGP
Aspire Growth Partners Miromar Lakes, Florida $146M AUM 22.8% 1-Year Est. Return
SIM
Sentry Investment Management Stevens Point, Wisconsin $146M AUM 23.67% 1-Year Est. Return
AC
Anson Capital Tyrone, Georgia $146M AUM 18.69% 1-Year Est. Return
ECM
Endure Capital Management Austin, Texas $146M AUM

22NW LP's Q3 2025 Portfolio in Review

As of Q3 2025, 22NW LP held 23 positions worth $212M, up 34% from $159M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

22NW LP's Q3 2025 filing shows 2 new, 4 increased, 5 reduced and 2 closed positions. Its largest new stake was Rezolute: 820,653 shares worth $7.71M. The largest sale was Mineralys Therapeutics, an estimated $4.36M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 48% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • 22NW LP's largest Q3 2025 buy was Rezolute: 820,653 shares worth $7.71M.
  • 22NW LP added most to Nektar Therapeutics in Q3 2025, an estimated $6.12M increase.
  • 22NW LP's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $4.36M.
  • 22NW LP fully exited Arvinas in Q3 2025, selling an estimated $3.04M.
  • 22NW LP's ten largest holdings make up 82% of its $212M portfolio in Q3 2025.
  • 22NW LP opened 2 new positions and closed 2 in Q3 2025.
  • 22NW LP's portfolio value rose 34% quarter-over-quarter to $212M.

Based on 22NW LP's 13F filing for Q3 2025, filed 14 Nov 2025.